March 01, 2015 2:47 AM ET

Biotechnology

Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the provision of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical trials reduces the severity of nonalcoholic steatohepatitis and plasma glucose. Zafgen, Inc. was founded in 2005 and is headquartered in Cambridge, Massa...

One Broadway

8th Floor

Cambridge, MA 02142

United States

Founded in 2005

18 Employees

Phone:

617-401-3051

Key Executives for Zafgen, Inc.

Chief Executive Officer and Director
Age: 54
Total Annual Compensation: $425.0K
President
Age: 51
Total Annual Compensation: $195.4K
Chief Financial Officer
Age: 51
Total Annual Compensation: $297.9K
Chief Medical Officer
Age: 43
Total Annual Compensation: $407.0K
Chief Commercial Officer
Age: 51
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

Zafgen, Inc. Key Developments

Zafgen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM

Zafgen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.

Zafgen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM

Zafgen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.

Zafgen Announces Positive Results from Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity

Zafgen announced that ZAF-221, a randomized, double-blind, placebo-controlled Phase 2 clinical trial of beloranib, a MetAP2 inhibitor, in 14 adults with hypothalamic injury associated obesity, or HIAO, met the primary efficacy endpoint of weight reduction (p = 0.01). In addition, beloranib treatment was well-tolerated and improved cardiovascular disease risk factors. HIAO is a rare form of medically induced obesity resulting from damage to the hypothalamus following resection of central nervous system tumors such as craniopharyngioma. The hypothalamus is a homeostatic control center in the brain that provides oversight of multiple hormonal systems, metabolic rate, hunger, and satiety. Patients affected by HIAO fail to regulate metabolism and food intake normally, resulting in rapid and intractable weight gain, treatment resistant severe obesity, and associated co-morbidities. Beloranib, a first-in-class MetAP2 inhibitor, that has demonstrated the potential to address weight loss and hunger reduction in patients with obesity, is being studied for the treatment of multiple indications. ZAF-221 was a randomized, double-blind, placebo controlled study of twice-weekly subcutaneous injections of 1.8 mg beloranib or placebo in patients with HIAO to evaluate weight reduction and safety over four weeks, followed by an optional four week open-label extension. Beloranib treatment resulted in mean weight loss of 3.4 kg and 6.2 kg in patients with HIAO after four and eight weeks of treatment with beloranib, respectively, in contrast to 0.3 kg mean weight loss in patients treated with placebo for four weeks (p= 0.01). Improvements in cardiovascular disease risk factors of lipids and inflammation (measured by C-reactive protein) were also observed. Beloranib 1.8 mg was well tolerated in this population, with no serious or severe adverse events reported. Safety measures such as laboratory, electrocardiogram, and vital sign measurements revealed no signals of concern, and all subjects randomized to beloranib completed the trial. This trial enrolled 14 obese patients (nine women and five men) who were confirmed by magnetic resonance imaging (MRI) to have had hypothalamic injury.

Similar Private Companies By Industry

Company Name Region
Gahaga Biosciences, Inc. United States
DNA Plant Technology Corp United States
FirstString Research, Inc. United States
AlphaVax, Inc. United States
Apollo Biopharmaceutics United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zafgen, Inc., please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.